-+ 0.00%
-+ 0.00%
-+ 0.00%

NewcelX reports Stem Cell Reports study shows AstroRx cell therapy boosts remyelination in MS models

PUBT·06/15/2026 12:43:02
Listen to the news
NewcelX reports Stem Cell Reports study shows AstroRx cell therapy boosts remyelination in MS models
  • NewcelX announced publication of a peer-reviewed study evaluating AstroRx, an embryonic stem cell-derived astrocyte therapy, for multiple sclerosis.
  • Results have already been presented via the Stem Cell Reports publication.
  • The study found AstroRx supported repair processes tied to remyelination in lab work and an animal model, suggesting potential in chronic demyelinating diseases.
  • The update extends evidence beyond a previously completed Phase 1/2a ALS trial, broadening the platform’s potential commercial scope.
  • Management highlighted continued focus on advancing NCEL-101 for type 1 diabetes alongside development of additional stem-cell-derived assets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-068524), on June 15, 2026, and is solely responsible for the information contained therein.